Hepatitis C Management in Special Populations
Summary
- Highly active DAA regimens are recommended as part of preferred or alternative regimens for HCV/HIV-coinfected patients by the AASLD/IDSA (Management Guidelines)[AASLD-IDSA HCV] and EASL (Management Guidelines)[EASL HCV] guidance panels Genotype 1 HCV/HIV Coinfection
- AASLD/IDSA and EASL guidance panels recommend highly active DAA regimens for genotype 1 HCV/HIV–coinfected patients (Management Guidelines)[AASLD-IDSA HCV] (Management Guidelines)[EASL HCV]
- AASLD/IDSA guidance panel recommends highly active DAA regimens as preferred therapy for genotype 2-6 HCV infection in HCV/HIV-coinfected patients (Management Guidelines)[AASLD-IDSA HCV]
Action required
- Login now to access all of your entitled content
or - View additional options to gain access to this content